Welcia (3141) Q4 2025 earnings summary

Executive summary

• AEON, Tsuruha Holdings, and Welcia Holdings announced a business integration to form Japan's largest drugstore network, aiming for robust partnerships and community health impact.

• The alliance targets prevention, healthcare, treatment, and wellness, with a focus on local communities and employee growth.

• Net sales rose 5.6% year-over-year to ¥1,285,005 million, but operating income fell 15.8% and net income dropped 43.5% to ¥14,958 million.

• Growth in dispensing division and private brand products was offset by discontinuation of cigarette sales and intensified competition.

• Store count reached 3,013 after 78 openings and 55 closures, with several acquisitions expanding the business.

Financial highlights

• Combined sales for Tsuruha and Welcia reach 2,312.4 billion yen, with 5,659 stores and 116,343 employees as of February 2025.

• The integrated group commands a 25.04% market share, ranking No. 1 in Japan's drugstore sector.

• Mid- to long-term targets (FY2/2032): 3 trillion yen in sales, 7% operating profit margin, and 210 billion yen operating income.

• Gross profit increased to ¥390,356 million, but operating margin declined to 2.8% from 3.6% year-over-year.

• Net assets rose to ¥254,486 million, equity ratio at 42.8%.

Outlook and guidance

• Six-year post-integration goals include 3 trillion yen in sales and 7% operating profit margin.

• Synergy effects expected to generate 50 billion yen in additional value within three years, before goodwill amortization.

• For the six months ending August 31, 2025, forecasts: net sales ¥685,100 million (+8.6%), operating income ¥20,500 million (+8.6%), net income attributable to owners of parent ¥12,500 million (+6.7%).

• No full-year forecast due to planned business integration and delisting.

• Strategic focus on remodeling stores, expanding dispensing pharmacies, and developing private brands under "Welcia 2.0".